|Trade names||Masivet, Kinavet|
|AHFS/Drugs.com||International Drug Names|
|Chemical and physical data|
|Molar mass||498.64 g/mol|
|3D model (JSmol)|
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it was distributed under the name Kinavet, however the FDA made Kinavet illegal in the US effective December 2015, therefore the use of the drug is no longer allowed in the US at this time. Masitinib is being studied for several human conditions including cancers, Alzheimer, multiple sclerosis, mastocytosis, and amyotrophic lateral sclerosis. It is being studied in Europe for orphan diseases.
Mechanism of action
Masitinib inhibits the receptor tyrosine kinase c-Kit which is displayed by various types of tumour. It also inhibits the platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR).
- Hahn, K.A.; Oglivie, G.; Rusk, T.; Devauchelle, P.; Leblanc, A.; Legendre, A.; Powers, B.; Leventhal, P.S.; Kinet, J.-P.; Palmerini, F.; Dubreuil, P.; Moussy, A.; Hermine, O. (2008). "Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors". Journal of Veterinary Internal Medicine. 22 (6): 1301–1309. doi:10.1111/j.1939-1676.2008.0190.x. ISSN 0891-6640.
- Information about Masivet at the European pharmacy agency website
- Orphan designation for Masitinib at the European pharmacy agency website
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|